Author(s):
Geetha. P, Bharathi. D, Deepa. N, Gopi. G, Shamshath Begum, Devi. T
Email(s):
lgeethapharma@gmail.com
DOI:
10.52711/2231-5713.2025.00043 
Address:
Geetha. P1*, Bharathi. D1, Deepa. N1, Gopi. G1, Shamshath Begum1, Devi. T2
1Faculty of Pharmacy, Sree Balaji Medical Collage and Hospital Campus, BIHER, Chromepet, Chennai.
2Chettinad School of Pharmaceutical Sciences, Chettinad Academy of Research and Education, Chettinad Hospital and Research Institute, Kelambakkam, Chennai.
*Corresponding Author
Published In:
Volume - 15,
Issue - 3,
Year - 2025
ABSTRACT:
One of the major side effects of diabetes mellitus (DM) that raises the rates of morbidity and death is diabetic cardiovascular autonomic neuropathy (CAN). As an antioxidant, alpha lipoic acid shows promise in lowering autonomic neuropathy. 138 participants with type 2 DM participated in the prospective observational research. Autonomic function, biochemical markers, and baseline demographics were measured. Patients receiving anti-diabetic medicine and oral dose of 200 mg of alpha lipoic acid for complications were observed for three months. Prior to and following the three-month period, the autonomic nerve system index (ANS) score was assessed. The ANS index score significantly decreased, and the neuropathy was found to have improved. There was statistical significance in the results. The study's conclusions demonstrated alpha lipoic acid's possible advantages in CAN management.
Cite this article:
Geetha. P, Bharathi. D, Deepa. N, Gopi. G, Shamshath Begum, Devi. T. Effectiveness of Alpha Lipoic Acid in Type 2 Diabetes Mellitus patients with Cardiac Autonomic Neuropathy. Asian Journal of Pharmacy and Technology. 2025; 15(3):286-8. doi: 10.52711/2231-5713.2025.00043
Cite(Electronic):
Geetha. P, Bharathi. D, Deepa. N, Gopi. G, Shamshath Begum, Devi. T. Effectiveness of Alpha Lipoic Acid in Type 2 Diabetes Mellitus patients with Cardiac Autonomic Neuropathy. Asian Journal of Pharmacy and Technology. 2025; 15(3):286-8. doi: 10.52711/2231-5713.2025.00043 Available on: https://ajptonline.com/AbstractView.aspx?PID=2025-15-3-11
REFERENCES:
1. World health organization. https://www.who.int/health-topics/diabetes#tab=tab_1
2. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003; 26:1553–1579.
3. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care. 2003; 6:1895–1901.
4. Maser R, Lenhard M, DeCherney G. Cardiovascular autonomic neuropathy: the clinical significance of its determination. Endocrinologist.2000;10:27–33.
5. Schumer MP, Joyner SA, Pfeifer MA. Cardiovascular autonomic neuropathy testing in patients with diabetes. Diabet Spectr. 1998; 11:227–223.
6. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285–2293.
7. Anonymous. Assessment: clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1996; 46: 873–880
8. Fisher VL, Tahrani AA. Cardiac autonomic neuropathy in patients with diabetes mellitus: Current perspectives. Diabetes Metab Syndr Obes. 2017; 10:419–34.
9. Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes. 2014; 5:17–39.
10. Verrotti A, Prezioso G, Scattoni R, Chiarelli F. Autonomic neuropathy in diabetes mellitus. Front Endocrinol (Lausanne). 2014 Dec 1; 5:205. doi: 10.3389/fendo.2014.00205. PMID: 25520703; PMCID: PMC4249492.
11. Tandon N, Ali MK, Narayan KM. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000. PMID: 22217193.
12. Tankova T, Cherninkova S, Koev D (2005) Treatment for diabetic mononeuropathy with alpha-lipoic acid. Int J Clin Pract 59:645–650.
13. Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997 Sep;46 Suppl 2: S62-6. doi: 10.2337/diab.46.2. s62. PMID: 9285502.
14. Lee SJ, Jeong SJ, Lee YC, Lee YH, Lee JE, Kim CH, Min KW, Cha BY. Effects of High-Dose α-Lipoic Acid on Heart Rate Variability of Type 2 Diabetes Mellitus Patients with Cardiac Autonomic Neuropathy in Korea. Diabetes Metab J. 2017 Aug;41(4):275-283. doi: 10.4093/dmj.2017.41.4.275. PMID: 28868825; PMCID: PMC5583405.
15. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, Gries FA. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995 Dec;38(12):1425-33. doi: 10.1007/BF00400603. PMID: 8786016.
16. Dan Ziegler, Helmut Schatz, Frank Conrad, F Arnold Gries, Heinz Ulrich, The DEKAN Study Group, Gerhard Reichel; Effects of Treatment with the Antioxidant α-Lipoic Acid on Cardiac Autonomic Neuropathy in NIDDM Patients: A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care 1 March 1997; 20 (3): 369–373. https://doi.org/10.2337/diacare.20.3.369
17. Serhiyenko, V., K. Kozlovska, and A. Serhiyenko. “Alpha-Lipoic Acid: Effects on the Beat-to-Beat Vectorcardiographic Parameters in Type 2 Diabetes Mellitus Patients with Cardiac Autonomic Neuropathy”. Journal of Endocrinology Research, vol. 2, no. 2, July 2020, pp. 16-21, doi:10.30564/jer. v2i2.2750.